Compare Natera Inc. Common Stock (NTRA) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ventas Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Ventas Inc. Common Stock trades at $85.53 (market cap $43.01B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Ventas Inc. Common Stock pays a 2.48% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ventas Inc. Common Stock for 6 Days on average.
| NTRA | VTR | |
|---|---|---|
Market Cap | $57.03B | $43.01B |
Volume | 1,131,157 | 4,035,460 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $100.53 |
52-Week Low | $179.42 | $68.89 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $55.73B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Ventas (VTR) trades at $83.85, up 0.37% today, amid a bearish technical signal with resistance near $84. The REIT reported Q2 2026 EPS of $0.14, slightly missing expectations, but maintains strong revenue growth with 2026 guidance at $6.4B. Analyst sentiment is positive with a $99.14 consensus target, supported by demographic tailwinds in senior housing.
The outlook for VTR is cautiously optimistic, driven by aging population trends boosting demand for senior housing. Risks include high valuation multiples and negative cash flow from aggressive investing. Wall Street's buy ratings (56%) suggest confidence in long-term growth, but investors should monitor earnings consistency and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
